Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Single Dose Ceftolozane/Tazobactam in Pediatric Patients
NCT02266706Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2014
- Primary completion
- Jun 2017
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 1, open-label trial of ceftolozane and tazobactam in Gram-negative bacterial infection (6 cohorts), sponsored by Merck & Co. Primary endpoints: Maximum Plasma Concentration at 6 hours, Time to Maximum Plasma Concentration at 6 hours and 4 more. Started Sep 2014; status: completed.
02
Drugs
ceftolozanetazobactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT02266706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266706.